AstraZeneca has put a hold on the late-stage trial of its highly-anticipated Covid-19 vaccine candidate after a suspected serious adverse reaction in a study participant, health news website Stat News reported on Tuesday.
It quoted an AstraZeneca spokesperson as saying in a statement that the “standard review process triggered a pause to vaccination to allow review of safety data.”
The vaccine developed by AstraZeneca in partnership with the University of Oxford is one of the most promising being tested around the world, in sites that include Brazil, the United States and the United Kingdom, where the adverse event was reported.
In June, the Brazilian government signed a $127 million agreement to start producing the vaccine in the country, in partnership with the Osvaldo Cruz Foundation (FioCruz).
Mexican and Argentine governments have also signed a partnership with AstraZeneca to initially produce 150 million doses destined for the whole Latin America.
The nature of the safety issue and when it happened were not immediately known, although the participant is expected to recover, according to Stat News.
The report said suspension of the trial was having an impact on other AstraZeneca vaccine trials – as well as on clinical trials being conducted by other vaccine makers.